Cell-based Therapies for Cancer
Prof. Carl June, MD
University of Pennsylvania
Carl June is recognized for his work in pioneering the development of CAR T therapy for cancer. He is currently Director of the Center for Cellular Immunotherapies at the Perelman School of Medicine, and Director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania. He maintains a research laboratory that studies various mechanisms of lymphocyte activation that relate to immune tolerance and adoptive immunotherapy for cancer and chronic infection. In 2011, his research team published findings detailing a new therapy in which patients with refractory and relapsed chronic lymphocytic leukemia were treated with genetically engineered versions of their own T cells. The treatment has been approved by the US FDA in 2017 as tisagenlecleucel for leukemia and lymphoma. He has published more than 450 manuscripts and is the recipient of numerous prizes and honors.

The HMZ Lecture Series on “Translation in Medicine” intends to bring the Zurich community together within the framework of top-class lectures.